Literature DB >> 2045172

Role of endothelium-derived relaxing factor in regulation of vascular tone and remodeling. Update on humoral regulation of vascular tone.

J P Tolins1, P J Shultz, L Raij.   

Abstract

In addition to preserving the permselectivity of the vascular wall and providing an antithrombogenic surface, the vascular endothelium contributes importantly to the regulation of vasomotor tone. Indeed, the endothelium participates in the conversion of angiotensin I to angiotensin II; the enzymatic inactivation of several plasma constituents such as bradykinin, norepinephrine, serotonin, and ADP; and the synthesis and release of vasodilator substances such as prostacyclin and the recently discovered endothelium-derived relaxing factor (EDRF). The diffusible EDRF released from the endothelium is nitric oxide or a substance closely related to it such as nitrosothiol. The endothelium also synthesizes and releases vasoconstrictive factors, including products derived from arachidonic acid metabolism and the recently discovered peptide endothelin. An increasing body of evidence from experimental and clinical studies indicates that EDRF and endothelium-derived contracting factors play an important role in vascular physiology and pathology. It has become apparent that the balance of these factors may be a major determinant of systemic and regional hemodynamics. Moreover, through generally opposite effects on growth-related vascular changes, contracting factors such as endothelin and relaxing factors such as EDRF also may be important determinants of the vascular response to injury in various disease states such as atherosclerosis and hypertension. It is clear that the vascular endothelium is a complex and dynamic organ. Understanding endothelium function in normal physiology and disease states is of potential clinical importance and should be the focus of future investigation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2045172     DOI: 10.1161/01.hyp.17.6.909

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  5 in total

1.  Angiotensin II is involved in nitric oxide synthase and cyclo-oxygenase inhibition-induced leukocyte-endothelial cell interactions in vivo.

Authors:  A Alvarez; L Piqueras; R Bello; A Canet; L Moreno; P Kubes; M J Sanz
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

2.  An experimental study of gastric mucosal blood flow in endotoxemia of the rat, with special reference to the vagus nerve and EDRF.

Authors:  T Sakano; K Itoh; M Tanaka; Y Arakawa; Y Matsuo
Journal:  J Gastroenterol       Date:  1995-02       Impact factor: 7.527

3.  Adaptation to increased dietary salt intake in the rat. Role of endogenous nitric oxide.

Authors:  P J Shultz; J P Tolins
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

4.  Remifentanil pretreatment ameliorates H/R-induced cardiac microvascular endothelial cell dysfunction by regulating the PI3K/Akt/HIF-1α signaling pathway.

Authors:  Xiaojun Li; Zhenping Gui; Huizi Liu; Shaojie Qian; Yanan Jia; Xiaopan Luo
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  Gold nanoparticles reduce high glucose-induced oxidative-nitrosative stress regulated inflammation and apoptosis via tuberin-mTOR/NF-κB pathways in macrophages.

Authors:  Huma Rizwan; Jagdeep Mohanta; Satyabrata Si; Arttatrana Pal
Journal:  Int J Nanomedicine       Date:  2017-08-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.